FDA Advisors Endorse JN.1-Based COVID Vaccine for Fall
TL;DR Summary
The FDA's advisory committee has unanimously recommended updating the Covid-19 vaccine to target the JN.1 lineage for the 2024-2025 season. This new monovalent vaccine aims to improve protection against the most common variants currently in circulation. The decision now awaits full FDA approval, with manufacturers like Pfizer, Moderna, and Novavax prepared to supply the updated shots by fall. Despite low current Covid-19 cases and hospitalizations, experts emphasize the need for updated vaccinations to maintain protection, especially as immunity from previous shots wanes over time.
- FDA vaccine advisers vote unanimously in favor of updated Covid-19 shot for fall CNN
- FDA panel supports switch to JN.1 for fall COVID vaccines University of Minnesota Twin Cities
- COVID shots should target variants with JN.1 lineage in 2024-25 campaign, US FDA advisers say Reuters
- FDA Advisors Give a Hearty Thumbs Up to a COVID Vaccine Based on the JN.1 Strain Medpage Today
- New Covid Vaccine Endorsed for Fall The New York Times
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 5 min read
Condensed
90%
814 → 84 words
Want the full story? Read the original article
Read on CNN